AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.34
-0.00 (-1.45%)
At close: 3:54PM EST
Stock chart is not supported by your current browser
Previous Close0.34
Open0.34
Bid0.34 x 0
Ask0.34 x 0
Day's Range0.33 - 0.34
52 Week Range0.14 - 0.48
Volume311,717
Avg. Volume344,054
Market Cap24.259M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • Marketwired11 days ago

    Aequus Announces Proposed $300,000 Equity Financing

    NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing,...

  • PR Newswire11 days ago

    CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders

    OTTAWA, Jan. 11, 2018 /PRNewswire/ - CannaRoyalty Corp. (CSE:CRZ) (CNNRF) ("CannaRoyalty") and Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus") (together the "Partners"), today announced a collaboration (the "JV") to advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders. CannaRoyalty and Aequus have formed this collaboration to clinically advance a number of cannabis-based therapies in partnership with Canadian clinicians to create truly differentiated products supported by clinical data focused on the medical community.

  • CNW Group11 days ago

    CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders

    OTTAWA, Jan. 11, 2018 /CNW/ - CannaRoyalty Corp. (CSE:CRZ) (OTCQX:CNNRF - News) ("CannaRoyalty") and Aequus Pharmaceuticals Inc. (TSX-V:AQS.V - News) (OTCQB:AQSZF - News) ("Aequus") (together the "Partners"), today announced a collaboration (the "JV") to advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders. CannaRoyalty and Aequus have formed this collaboration to clinically advance a number of cannabis-based therapies in partnership with Canadian clinicians to create truly differentiated products supported by clinical data focused on the medical community.

  • Marketwiredlast month

    Aequus announces the issuance of stock options

    Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the issuance of stock options...

  • Marketwired2 months ago

    Aequus Provides Third Quarter 2017 Operational Highlights

    Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three...

  • Marketwired2 months ago

    Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

    Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent...

  • Marketwired3 months ago

    Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

    Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the State Intellectual...

  • Baystreet5 months ago

    Stocks in play: Aequus Pharmaceuticals Inc.

    Has received a receipt for its final short form base shelf prospectus. The Prospectus will allow Aequus ...